Failure in cancer drug development exacts heavy burdens on patients and research
systems. To investigate inefficiencies and burdens in targeted drug development in cancer …

Since 2010, six drugs have been approved for the treatment of castration-resistant prostate
cancer, ie, CYP17 inhibitor Abiraterone, androgen receptor antagonist Enzalutamide …

Progress in understanding the disease biology and mechanisms of castration resistance led
to significant therapeutic advancements, particularly in the setting of mCRPC in which …

Polypharmacy increases the risk of drug–drug interactions (DDIs). Combining
epidemiological studies with pharmacokinetic modeling, we detected and evaluated high …

After many years of limited treatment options for patients with metastatic castration-resistant
prostate cancer (mCRPC), multiple systemic therapies are now available, providing patients …

After prostatectomy due to prostate carcinoma, patients often develop metastases. Although
prostate cancer is susceptible to hormonal manipulation, many patients become castration …

Background Sorafenib promotes apoptosis through downstream pathways that can be
deregulated in CRPC. We hypothesized that sorafenib could overcome chemotherapy …

索拉非尼是一种多靶点的酪氨酸激酶抑制剂, 主要治疗晚期肾癌, 肝癌. 药物-
药物相互作用引起的索拉非尼的药代动力学的变化可能影响其临床效果和安全性 …

The multi-kinase inhibitor sorafenib is used for the treatment of renal and hepatic
carcinomas and is undergoing evaluation for treatment of breast cancer in combination with …

Modern genomics has revealed that the biological source of human complexity is in the
regulation of gene expression, or the process of turning genes “on and off” and modulating …